seqirus
FDA approves first adjuvanted quadrivalent flu vaccine in over-65s
February 24, 2020Sales and Marketing FDA, flu, influenza, pharma, seqirus
The FDA has just authorised its first adjuvanted quadrivalent influenza vaccine, it has been announced. Seqirus’ Fluad Quadrivalent (influenza vaccine, adjuvanted) …
Seqirus’ Audenz becomes first FDA-approved cell-based adjuvant influenza A vaccine
February 5, 2020Research and Development, Sales and Marketing FDA, influenza, pharma, seqirus
The FDA has just approved the first adjuvanted, cell-based vaccine for the prevention of influenza A (H5N1) in the US, …
Beating the flu
February 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing flu, influenza, pharma, seqirus
On 14 January, the European Commission issued marketing approval for Flucelvax Tetra, the first cell-based, quadrivalent influenza vaccine. Pharmafocus spoke …
Seqirus secures first cell-based quadrivalent influenza vaccine approval in Europe
January 14, 2019Sales and Marketing Europe, Flucelvax, flu, influenza, pharma, seqirus
Seqirus has made it known that its new cell-based seasonal influenza vaccine Flucelvax Tetra has been approved by the European …
Seqirus announces £40m UK fill-and-finish flu vaccine facility
November 9, 2017Manufacturing and Production Liverppol, Novartis, UK, Vaccine, flu, influenza, pharma, seqirus
Seqirus, an influenza vaccine specialist subsidiary of global biotech firm CSL, has announced a £40 million investment into a new …
Newly adopted flu vaccine could save 1,700 lives
September 12, 2017Research and Development, Sales and Marketing biotech, drugs, flu, fluad, pharma, pharmaceutical, seqirus
The Fluad flu vaccine, produced by Seqirus, was approved by the MHRA for use beginning in 2018 and further data …
CSL’s flu vaccine scores FDA approval
May 24, 2016Manufacturing and Production, Research and Development, Sales and Marketing CSL, FDA, Vaccine, flu, four strain, four-strain, influenza, influenza a, influenza b, seqirus
Seqirus, a division of CSL, has announced that the US Food and Drug Administration (FDA) has approved Flucelvax Quadrivalent (influenza …
